“Relaxin-2”的搜索结果，显示 151-160 项，共有 7661 项

1. 神经科- 临床试验- 妙佑医疗国际

   ... 2 participants will also undergo MRI scanning, comprehensive cognitive ... (2) Cohort 2 focuses on primary or secondary myelofibrosis (MF) displaying ...

2. 神经科- 临床试验- 妙佑医疗国际

   The purpose of this study is to determine the maximum tolerated dose (MTD) and/or the recommended Phase 2 dose (RP2D) of WSD0922-FU in subjects with recurrent ...

3. 神经科- 临床试验- 妙佑医疗国际

   Cohort 3 includes (1) CMVpp65 absent and (2) CMVpp65 present GBM.. Patients in all subcohorts except 1.11 and 1.12 currently have unresectable advanced or ...

4. 神经科- 临床试验- 妙佑医疗国际

   Cohort 3 includes (1) CMVpp65 absent and (2) CMVpp65 present GBM.. Patients in all subcohorts except 1.11 and 1.12 currently have unresectable advanced or ...

5. 神经科- 临床试验- 妙佑医疗国际

   Cohort 3 includes (1) CMVpp65 absent and (2) CMVpp65 present GBM.. Patients in all subcohorts except 1.11 and 1.12 currently have unresectable advanced or ...

6. 神经科- 临床试验- 妙佑医疗国际

   Cohort 3 includes (1) CMVpp65 absent and (2) CMVpp65 present GBM.. Patients in all subcohorts except 1.11 and 1.12 currently have unresectable advanced or ...

7. 神经科- 临床试验- 妙佑医疗国际

   ... 2 participants will also undergo MRI scanning, comprehensive cognitive ... (2) Cohort 2 focuses on primary or secondary myelofibrosis (MF) displaying ...

8. 神经科- 临床试验- 妙佑医疗国际

   Cohort 3 includes (1) CMVpp65 absent and (2) CMVpp65 present GBM.. Patients in all subcohorts except 1.11 and 1.12 currently have unresectable advanced or ...

9. 神经科- 临床试验- 妙佑医疗国际

   Cohort 3 includes (1) CMVpp65 absent and (2) CMVpp65 present GBM.. Patients in all subcohorts except 1.11 and 1.12 currently have unresectable advanced or ...

10. 神经科- 临床试验- 妙佑医疗国际

    ... 2 or 3 meningioma as measured by 6-month PFS rate. Validation Of Early Prognostic Data For Recovery Outcome After Stroke For Future, Higher Yield Trials.